Literature DB >> 9080022

Short-term low dose intracoronary diltiazem administered at the onset of reperfusion reduces myocardial infarct size.

W R Herzog1, R A Vogel, M L Schlossberg, L R Edenbaum, H J Scott, V L Serebruany.   

Abstract

BACKGROUND: Currently, controversy exists regarding the use of calcium-channel blockers in the treatment of acute myocardial infarction (AMI), due to apparent conflicting results from clinical trials and animal models. One hypothesis to explain such a discrepancy proposes that the timing and duration of drug administration might influence its cardioprotective effect. Pretreatment with calcium-channel blockers or their administration during coronary artery occlusion is associated with the diminished infarct size in animal models. While verapamil failed to reduce infarct size when the drug was given at the onset of reperfusion, similar effects of low dose diltiazem are not known. METHODS AND
RESULTS: This experiment evaluated the effect of intracoronary short term low dose diltiazem administration given immediately with postischemic myocardial reperfusion. Yorkshire swine underwent thoracotomy and 50 min of left anterior descending (LAD) occlusion, followed by 3 h of reperfusion. In the first group, diltiazem (2.5 mg diluted in 60 cc saline) was infused into the LAD over 12 min, beginning with the onset of reperfusion (n=8). In the second group, animals received saline instead of diltiazem and served as controls (n=6). Infarct size was 0.13+/-0.06 g/kg of body weight for diltiazem group, and 0.42+/-0.04 g/kg for controls (P=0.01).
CONCLUSIONS: Short-term low dose diltiazem delivered exclusively during early reperfusion can significantly diminish infarct size in swine. Local intracoronary diltiazem may be valuable adjunct in patients subject to myocardial ischemia/reperfusion during coronary artery bypass grafting, primary angioplasty for AMI, or thrombolysis for AMI if given immediately after restoration of coronary blood flow.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9080022     DOI: 10.1016/s0167-5273(96)02883-5

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  8 in total

1.  Mitochondrial K+ channels are involved in ischemic postconditioning in rat hearts.

Authors:  Chunhong Jin; Jinrong Wu; Makino Watanabe; Takao Okada; Takafumi Iesaki
Journal:  J Physiol Sci       Date:  2012-04-19       Impact factor: 2.781

2.  Inhibitory effects of AMP 579, a novel cardioprotective adenosine A1/A2A receptor agonist, on native IKr and cloned HERG current.

Authors:  Noriko Saegusa; Toshiaki Sato; Takehiko Ogura; Issei Komuro; Haruaki Nakaya
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-11-19       Impact factor: 3.000

Review 3.  Myocardial ischemia-reperfusion injury: a neglected therapeutic target.

Authors:  Derek J Hausenloy; Derek M Yellon
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

4.  The cardioprotective effect of microemulsion propofol against ischemia and reperfusion injury in isolated rat heart.

Authors:  Min Jung Hur; Heezoo Kim; Dong Kyu Lee; Sang Ho Lim
Journal:  Korean J Anesthesiol       Date:  2012-04-23

Review 5.  Glutathionylation of the L-type Ca2+ channel in oxidative stress-induced pathology of the heart.

Authors:  Victoria P A Johnstone; Livia C Hool
Journal:  Int J Mol Sci       Date:  2014-10-22       Impact factor: 5.923

6.  Characterization of novel lncRNAs in upper thoracic spinal cords of rats with myocardial ischemia-reperfusion injuries.

Authors:  Zhi-Xiao Li; Yu-Juan Li; Qian Wang; Zhi-Gang He; Mao-Hui Feng; Hong-Bing Xiang
Journal:  Exp Ther Med       Date:  2021-02-11       Impact factor: 2.447

7.  New perspectives of nitric oxide donors in cardiac arrest and cardiopulmonary resuscitation treatment.

Authors:  Peter Kruzliak; Olga Pechanova; Tomas Kara
Journal:  Heart Fail Rev       Date:  2014-05       Impact factor: 4.214

8.  Hydroxysafflor Yellow A Protects Against Myocardial Ischemia/Reperfusion Injury via Suppressing NLRP3 Inflammasome and Activating Autophagy.

Authors:  Jingxue Ye; Shan Lu; Min Wang; Wenxiu Ge; Haitao Liu; Yaodong Qi; Jianhua Fu; Qiong Zhang; Bengang Zhang; Guibo Sun; Xiaobo Sun
Journal:  Front Pharmacol       Date:  2020-07-30       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.